A retrospective analysis in epidermal growth factor receptor-mutant (EGFR) NSCLC patients suggested that concurrent aspirin use with osimertinib (EGFR inhibitor) was associated with prolonged progression-free survival (Liu et al., 2020), and a similar result was also reported in NSCLC (Han et al., 2020). This evidence concerns the gene EGFR and non-small cell lung carcinoma.